Literature DB >> 12907804

Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model.

Brian K Kaspar1, Jerònia Lladó, Nushin Sherkat, Jeffrey D Rothstein, Fred H Gage.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive, lethal neuromuscular disease that is associated with the degeneration of spinal and brainstem motor neurons, leading to atrophy of limb, axial, and respiratory muscles. The cause of ALS is unknown, and there is no effective therapy. Neurotrophic factors are candidates for therapeutic evaluation in ALS. Although chronic delivery of molecules to the central nervous system has proven difficult, we recently discovered that adeno-associated virus can be retrogradely transported efficiently from muscle to motor neurons of the spinal cord. We report that insulin-like growth factor 1 prolongs life and delays disease progression, even when delivered at the time of overt disease symptoms.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12907804     DOI: 10.1126/science.1086137

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  278 in total

1.  Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2.

Authors:  Yu Miyazaki; Hiroaki Adachi; Masahisa Katsuno; Makoto Minamiyama; Yue-Mei Jiang; Zhe Huang; Hideki Doi; Shinjiro Matsumoto; Naohide Kondo; Madoka Iida; Genki Tohnai; Fumiaki Tanaka; Shin-ichi Muramatsu; Gen Sobue
Journal:  Nat Med       Date:  2012-07       Impact factor: 53.440

2.  IPLEX administration improves motor neuron survival and ameliorates motor functions in a severe mouse model of spinal muscular atrophy.

Authors:  Michela Murdocca; Arianna Malgieri; Andrea Luchetti; Luciano Saieva; Gabriella Dobrowolny; Elvira de Leonibus; Antonio Filareto; Maria Chiara Quitadamo; Giuseppe Novelli; Antonio Musarò; Federica Sangiuolo
Journal:  Mol Med       Date:  2012-09-25       Impact factor: 6.354

Review 3.  Complex genetics of amyotrophic lateral sclerosis.

Authors:  Catherine B Kunst
Journal:  Am J Hum Genet       Date:  2004-10-11       Impact factor: 11.025

4.  Preclinical safety validation of a stabilized viral vector direct injection approach to the cervical spinal cord.

Authors:  Thais Federici; Jonathan Riley; John Park; Mark Bain; Nicholas Boulis
Journal:  Clin Transl Sci       Date:  2009-04       Impact factor: 4.689

5.  Transient demyelination increases the efficiency of retrograde AAV transduction.

Authors:  Edmund R Hollis; Pouya Jamshidi; Ariana O Lorenzana; Jae K Lee; Steven J Gray; Richard J Samulski; Binhai Zheng; Mark H Tuszynski
Journal:  Mol Ther       Date:  2010-05-25       Impact factor: 11.454

6.  Correction of brain oligodendrocytes by AAVrh.10 intracerebral gene therapy in metachromatic leukodystrophy mice.

Authors:  Françoise Piguet; Dolan Sondhi; Monique Piraud; Françoise Fouquet; Neil R Hackett; Ornella Ahouansou; Marie-Thérèse Vanier; Ivan Bieche; Patrick Aubourg; Ronald G Crystal; Nathalie Cartier; Caroline Sevin
Journal:  Hum Gene Ther       Date:  2012-07-23       Impact factor: 5.695

7.  Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy.

Authors:  Ferrill F Rose; Virginia B Mattis; Hansjörg Rindt; Christian L Lorson
Journal:  Hum Mol Genet       Date:  2008-12-12       Impact factor: 6.150

8.  Systemic administration of a recombinant AAV1 vector encoding IGF-1 improves disease manifestations in SMA mice.

Authors:  Li-Kai Tsai; Chien-Lin Chen; Chen-Hung Ting; Sue Lin-Chao; Wuh-Liang Hwu; James C Dodge; Marco A Passini; Seng H Cheng
Journal:  Mol Ther       Date:  2014-05-12       Impact factor: 11.454

9.  Amelioration of laminin-alpha2-deficient congenital muscular dystrophy by somatic gene transfer of miniagrin.

Authors:  Chunping Qiao; Jianbin Li; Tong Zhu; Romesh Draviam; Simon Watkins; Xiaojing Ye; Chunlian Chen; Juan Li; Xiao Xiao
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-15       Impact factor: 11.205

Review 10.  Therapeutic gene silencing in neurological disorders, using interfering RNA.

Authors:  G Scott Ralph; Nicholas D Mazarakis; Mimoun Azzouz
Journal:  J Mol Med (Berl)       Date:  2005-03-10       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.